表紙
市場調査レポート

T細胞白血病:世界の治験レビュー

T-Cell Leukemia Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 230749
出版日 ページ情報 英文 125 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
T細胞白血病:世界の治験レビュー T-Cell Leukemia Global Clinical Trials Review, H1, 2014
出版日: 2014年05月21日 ページ情報: 英文 125 Pages
概要

当レポートでは、T細胞白血病に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • T細胞白血病
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の上位5ヶ国
    • 欧州の上位5ヶ国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国での治験件数:腫瘍性疾患の治験全体におけるT細胞白血病の割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:腫瘍性疾患の治験全体におけるT細胞白血病の割合

E7諸国での治験件数:フェーズ(相)別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • T細胞白血病治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • キリンホールディングス
    • BioCryst Pharmaceuticals, Inc.
    • Celgene Corporation
    • 大塚ホールディングス
    • Novartis AG
    • Mundipharma International Limited
    • GlaxoSmithKline plc
    • Angimmune LLC
  • 代表的な研究機関・病院の治験の概要
    • National Cancer Institute
    • Fred Hutchinson Cancer Research Center
    • 厚生労働省
    • University of Washington
    • JCOG(日本臨床腫瘍研究グループ)
    • Memorial Sloan Kettering Cancer Center
    • National Heart, Lung, and Blood Institute
    • The University of Texas M. D. Anderson Cancer Center
    • Washington University School of Medicine
    • Thomas Jefferson University

5つの代表的な治験のプロファイル

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC2146CTIDB

GlobalData's clinical trial report, "T-Cell Leukemia Global Clinical Trials Review, H1, 2014" provides data on the T-Cell Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on T-Cell Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating T-Cell Leukemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • T-Cell Leukemia
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of T-Cell Leukemia to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of T-Cell Leukemia to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of T-Cell Leukemia
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in T-Cell Leukemia Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on T-Cell Leukemia
    • Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-Cell Leukemia-Lymphoma In US And Europe
    • Apr 09, 2012: Study Demonstrates Potential Of New Anti-Leukemia Compound, Lenaldekar
    • Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity
    • Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Kirin Holdings Company, Limited
      • Clinical Trial Overview of Kirin Holdings Company, Limited
      • BioCryst Pharmaceuticals, Inc.
      • Clinical Trial Overview of BioCryst Pharmaceuticals, Inc.
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
      • Otsuka Holdings Co., Ltd.
      • Clinical Trial Overview of Otsuka Holdings Co., Ltd.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Mundipharma International Limited
      • Clinical Trial Overview of Mundipharma International Limited
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Angimmune LLC
      • Clinical Trial Overview of Angimmune LLC
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Fred Hutchinson Cancer Research Center
      • Clinical Trial Overview of Fred Hutchinson Cancer Research Center
      • Ministry of Health, Labour and Welfare, Japan
      • Clinical Trial Overview of Ministry of Health, Labour and Welfare, Japan
      • University of Washington
      • Clinical Trial Overview of University of Washington
      • Japan Clinical Oncology Group
      • Clinical Trial Overview of Japan Clinical Oncology Group
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • National Heart, Lung, and Blood Institute
      • Clinical Trial Overview of National Heart, Lung, and Blood Institute
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • Washington University School of Medicine
      • Clinical Trial Overview of Washington University School of Medicine
      • Thomas Jefferson University
      • Clinical Trial Overview of Thomas Jefferson University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • T-Cell Leukemia Therapeutics, Global, Clinical Trials by Region, 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of T-Cell Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014*
  • T-Cell Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • T-Cell Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of T-Cell Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014*
  • T-Cell Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials by Phase, 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • T-Cell Leukemia Therapeutics, Global, Suspended Clinical Trials, 2014*
  • T-Cell Leukemia Therapeutics, Global, Terminated Clinical Trials, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • T-Cell Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Kirin Holdings Company, Limited, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by BioCryst Pharmaceuticals, Inc., 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Otsuka Holdings Co., Ltd., 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Mundipharma International Limited, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Angimmune LLC, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Ministry of Health, Labour and Welfare, Japan, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Japan Clinical Oncology Group, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2014*

List of Figures

  • T-Cell Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of T-Cell Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014*
  • T-Cell Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • T-Cell Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of T-Cell Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014*
  • T-Cell Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • T-Cell Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • T-Cell Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • T-Cell Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top